Novo Nordisk A/s

This completed study looked at the safety and effectiveness of the weight-loss drug Saxenda (liraglutide) in 300 obese adults and teenagers in Taiwan. Participants took the drug as part of their normal care for about 26 weeks. The main goal was to track any side effects and see h…

This study tested a new medicine called NNC0487-0111 for weight control in 36 Chinese adults with overweight or obesity. Participants received either the drug or a placebo injection. The main goal was to check safety and how the drug moves through the body. The trial lasted up to…

This study tested a new once-weekly injection called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help people with overweight or obesity and type 2 diabetes lose weight. About 1,200 adults received either CagriSema or a placebo for around 1.5 years. The …

This study tested a medicine called nonacog beta pegol (N9-GP) in 30 Chinese men with moderate to severe hemophilia B. The medicine is injected into a vein to help blood clot and prevent or treat bleeding episodes. The trial lasted about 12-16 months and checked how well the medi…

This completed Phase 1 trial tested the safety of a new drug called Inno8 in 95 healthy men. Participants received either Inno8 or a placebo by injection or as tablets. The study measured side effects and how the drug moves through the body. Results will help decide if Inno8 shou…

This study tests a new medicine, NNC0662-0419, for people who are overweight or obese. It is the first time the drug is given to humans, so the main goal is to check safety and how the body handles it. About 100 adults aged 19-55 with a BMI between 27 and 40 will receive either t…

This study tested a new approach for people with type 2 diabetes: a once-weekly insulin injection (insulin icodec) combined with a flash glucose monitor, a small sensor worn on the arm that tracks blood sugar continuously. The goal was to see if this combination helps control blo…

This completed Phase 1 trial tested CagriSema, a new combination of two medicines (cagrilintide and semaglutide), in 158 adults with type 2 diabetes. Participants received either CagriSema, one of the individual drugs, or a placebo, alongside their usual metformin. The study meas…

This study tested a new medicine called NNC0487-0111 in 448 adults with type 2 diabetes. Participants received either a once-weekly injection, a daily pill, or a placebo for about 43 weeks. The goal was to see how well different doses lower blood sugar and body weight.

This study followed 145 adults with type 2 diabetes who were prescribed oral semaglutide (Rybelsus) by their doctors. Researchers tracked changes in blood sugar (HbA1c) and body weight over 8-10 months. Participants also filled out questionnaires about how they took the medicatio…

This study tested a new medicine (NNC0480-0389) combined with semaglutide, a common diabetes drug, in 500 people with type 2 diabetes. Participants received weekly injections for about 41 weeks. The goal was to see how well the combination lowers blood sugar and to pick the best …

This early study tested a new medicine called NNC0363-1063 in 117 people, including healthy volunteers and those with type 1 diabetes. The goal was to check safety, how the body processes the drug, and its effects on blood sugar. It is a first step to see if this drug could becom…

This study tested whether a weekly injection of semaglutide (2.4 mg) helps teenagers with overweight or obesity lose weight. 201 teens aged 12 to 18 took part, receiving either semaglutide or a placebo for about 15 months, along with lifestyle counseling. The main goal was to see…

This study tested a daily 25 mg semaglutide pill in 307 adults with overweight or obesity over 64 weeks. Participants taking the drug lost more weight than those on placebo, with many achieving at least 5% body weight reduction. The pill offers a convenient alternative to injecti…

This completed Phase 3 trial tested whether a daily oral semaglutide tablet (50 mg) helps people with overweight or obesity lose weight. 667 adults took either the drug or a placebo for 68 weeks, along with diet and exercise counseling. The main goals were to measure percentage o…

This completed Phase 1 trial tested a new drug called NNC0519-0130 in 134 overweight or obese adults. The goal was to see if different ways of increasing the dose could reduce side effects. Participants received weekly or twice-weekly injections for about 24 weeks, and researcher…

This study tested whether a new way of making semaglutide works as well as the current version for controlling blood sugar in people with type 2 diabetes. 388 participants received weekly injections for about 8 months. The main goal was to compare changes in HbA1c levels between …

This study tested a new fast-acting insulin (NNC0471-0119) given through an insulin pump in 43 adults with type 1 diabetes. Researchers measured how quickly the insulin entered the bloodstream and lowered blood sugar, comparing it to a standard insulin (aspart). The goal was to s…

This study tested a new insulin called icodec that is taken just once a week, compared to a standard daily insulin (glargine), in 429 adults with type 2 diabetes. Participants received either the weekly or daily insulin for 6 months. The goal was to see if the weekly insulin work…

This study tested a new medicine called NNC0519-0130 in 299 adults with type 2 diabetes. The goal was to see if a once-weekly injection can lower blood sugar and body weight. Participants received up to 7 different doses for about 40 weeks. The results will help find the best dos…

This study tested a new medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help people with overweight or obesity lose weight. About 300 adults took part, receiving either CagriSema or a dummy shot once a week for around 1½ years. The main goal…

This study looked at whether using a mobile app called 'Dose Check' along with the insulin Tresiba helps people with type 2 diabetes control their blood sugar. About 179 adults in Saudi Arabia took part for 6-7 months. The app helps patients figure out the right insulin dose. The…

This study tested a new insulin called icodec that is injected just once a week, compared to standard insulins taken every day. Over 1,000 adults with type 2 diabetes who had never used insulin before took part. The goal was to see if the weekly insulin controls blood sugar just …

This study tested a new once-a-week injection called IcoSema, which combines insulin and semaglutide, against semaglutide alone in 683 adults with type 2 diabetes. The goal was to see if IcoSema improves blood sugar levels more effectively. Participants received weekly shots for …

This study tested a weekly injection of semaglutide (2.4 mg) in 207 adults with obesity and prediabetes. Participants received either the drug or a placebo for 12 months, plus lifestyle advice. The goal was to see how much weight they lost and whether their blood sugar returned t…

This study tested a new investigational drug called CagriSema against a currently available medicine, tirzepatide, in over 1,000 adults with type 2 diabetes. The goal was to see which works better at lowering blood sugar and body weight. Participants received weekly injections of…

This study tested whether a smartphone app helps people with type 2 diabetes stick with their weekly Ozempic injections. 304 participants either used the app or received standard care. The study tracked how long they stayed on the medication and if they reached their target dose.

This study tested a new medicine called turoctocog alfa pegol (N8-GP) in 124 children under 6 years old with severe haemophilia A who had never been treated before. The goal was to see if the medicine is safe and effective at preventing and treating bleeding episodes. The childre…

This study tested an experimental drug called etavopivat in 12 children and young adults (ages 12-21) with sickle cell disease. The goal was to see if the drug could improve blood flow and oxygen delivery to the brain and muscles. Participants took the drug and had scans to measu…

This study tested a new medicine, NNC6019-0001, in 105 adults with a heart disease caused by TTR amyloidosis, where abnormal proteins damage the heart. Participants received either the medicine or a placebo by infusion every 4 weeks for about 64 weeks. The goal was to see if the …

This study tested whether adding the drug semaglutide to a new weekly insulin (insulin icodec) helps lower blood sugar in people with type 2 diabetes whose blood sugar was not well controlled on insulin alone. 148 adults took part. First, everyone received weekly insulin for 26 w…

This study tested a new weekly injection called IcoSema, which combines two diabetes drugs (insulin icodec and semaglutide), against daily insulin glargine in 485 adults with type 2 diabetes whose blood sugar was not well controlled on oral medications. The goal was to see if the…

This completed Phase 3 study tested a high 7.2 mg weekly dose of semaglutide in 512 adults with obesity and type 2 diabetes. Participants received either the high dose, a lower dose, or a placebo injection, along with lifestyle counseling. The main goals were to measure weight lo…

This study tested a new once-weekly medicine called IcoSema, which combines insulin icodec and semaglutide, against once-weekly insulin icodec alone in over 1,200 people with type 2 diabetes. The goal was to see if IcoSema controls blood sugar better over 52 weeks. Participants i…

This study tested a new growth hormone medicine, somapacitan, given once a week, against the standard daily Norditropin in 200 children with growth hormone deficiency. After one year, children receiving the weekly shot grew just as much in height as those on daily shots, with sim…

This Phase 3 trial tested CagriSema, a once-weekly injection combining two medicines (cagrilintide and semaglutide), in 2734 adults with type 2 diabetes. The goal was to see if the combo lowers blood sugar and body weight better than either drug alone or a placebo. All participan…

This study looked at how well once-daily oral semaglutide (Rybelsus) works for adults with type 2 diabetes in everyday medical practice in Israel. Researchers tracked changes in blood sugar and body weight over about 8-10 months. The goal was to see if the pill helps lower blood …

This study tested a new medicine called NNC0519-0130, given as a weekly injection under the skin, to help people with excess body weight lose weight. About 354 adults with overweight or obesity took part, receiving different doses of the drug, a placebo, or an existing weight-los…

This study followed 336 adults with type 2 diabetes in the UK who were prescribed oral semaglutide (Rybelsus) by their doctors. Over 8-10 months, researchers tracked changes in blood sugar levels and body weight, and asked participants about their medication use. The goal was to …

This completed study followed more than 3,200 Japanese adults with type 2 diabetes who were prescribed Ozempic (semaglutide) by their doctors. Over about 3 years, researchers monitored side effects and checked how well the drug controlled blood sugar and weight. The goal was to s…

This completed study tested the safety and tolerability of a once-weekly injection of semaglutide (0.5 or 1.0 mg) in 104 Chilean adults with type 2 diabetes. Participants received the drug for 24 weeks, with regular blood and urine tests. The main goal was to count any side effec…

This completed Phase 3 trial tested whether oral semaglutide, a drug used for diabetes, can slow cognitive decline in 1840 people with early Alzheimer's disease. Participants took either the drug or a placebo daily for up to 3 years and 4 months. Researchers measured changes in m…

This study tested a new weekly injection called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help Chinese adults with obesity or overweight lose weight. About 300 participants received either CagriSema, semaglutide alone, or a placebo for around one year…

This study tested whether a daily pill called oral semaglutide helps children and teenagers (ages 10 to under 18) with type 2 diabetes control their blood sugar better than a placebo. All participants also took metformin and/or insulin. The study lasted about 15 months and includ…

This completed study in Finland looked at how once-daily oral semaglutide (Rybelsus) works in adults with type 2 diabetes. Researchers tracked changes in blood sugar and body weight over 8-10 months in 50 participants. The goal was to see if the drug helps lower blood sugar in ev…

This study tested a new medicine called Mim8, given as a shot under the skin, to prevent bleeding episodes in children aged 1-11 with hemophilia A (with or without inhibitors). The trial involved 70 participants and compared once-weekly and once-monthly dosing over about 54-98 we…

This completed study followed 465 adults with type 2 diabetes in Spain who were already prescribed oral semaglutide (Rybelsus) by their doctors. Researchers tracked changes in blood sugar (HbA1c), body weight, and how satisfied patients were with the treatment over 8-10 months. T…

This early-stage trial studied how ziltivekimab works in the body of 24 Chinese adults with chronic kidney disease and signs of inflammation. Participants received either the drug or a placebo as three injections over several weeks. The study measured drug levels and safety, with…

This completed study in Mexico followed 187 adults with type 2 diabetes who were already prescribed oral semaglutide (Rybelsus) by their doctor. The goal was to see how well the once-daily pill lowers blood sugar and affects body weight over 8-10 months. Participants also filled …

This study tested a new investigational medicine called CagriSema, which combines two drugs (cagrilintide and semaglutide) in one weekly injection. It was given to 274 adults with type 2 diabetes who were already taking daily insulin, with or without metformin. The goal was to se…

This study tested whether combining two injectable drugs, cagrilintide and semaglutide, works better than either drug alone for lowering blood sugar in people with type 2 diabetes. 92 adults with type 2 diabetes and a BMI of 27 or higher took part. Participants received weekly in…

This study tested a medicine called turoctocog alfa pegol (N8-GP) in 36 Chinese men with severe hemophilia A, a bleeding disorder. The drug helps blood clot and was given as an injection to prevent or stop bleeding episodes. The trial lasted about 7-8 months and measured how many…

This study tested a new medicine, somapacitan, given once a week against the standard daily growth hormone shot (Norditropin®) in 110 Chinese children with growth hormone deficiency. The goal was to see if the weekly shot works as well as the daily one for helping children grow. …

This study tested whether combining a new liver drug (NNC0194-0499) with semaglutide (a diabetes/weight-loss drug) can reduce liver scarring in people with NASH, a serious fatty liver disease. About 700 adults received weekly injections of either the drug combo, a different combo…

This study looked at the safety and effectiveness of Fiasp®, a fast-acting mealtime insulin, in 42 adults with type 1 or type 2 diabetes. Participants used Fiasp® as prescribed by their doctor for about 6 months. Researchers tracked side effects and blood sugar control to see how…

This study tested a high dose (7.2 mg) of semaglutide, a once-weekly injection, in 1407 adults with obesity. Participants also received lifestyle advice. The main goal was to see how much weight they lost compared to those on a lower dose or placebo. Results showed significant we…

This study tested whether adding a weekly semaglutide injection to a lower dose of insulin works as well as a higher dose of insulin alone for controlling blood sugar in people with type 2 diabetes who are overweight. About 573 adults took part for roughly 11 months. The goal was…

This study followed 28 people with hemophilia B in Japan who were already prescribed Refixia as part of their normal care. Researchers tracked side effects, bleeding episodes, and quality of life to confirm the drug's safety and effectiveness over time. The study did not test a n…

This study looked at how well Rybelsus (oral semaglutide) works for adults with type 2 diabetes in Italy. Researchers tracked blood sugar levels and weight changes over 8-10 months in 458 people already prescribed the drug by their doctor. The goal was to see if the medicine help…

This study tested a weekly injection of semaglutide (2.4 mg) to help adults with overweight or obesity lose weight. About 242 people took part, comparing the drug to a placebo over roughly one year. The main goal was to see how much weight they lost and how many lost at least 5% …

This study followed 650 adults with type 2 diabetes in Japan who were prescribed oral semaglutide (Rybelsus®) by their doctors. The goal was to see how well the once-daily pill lowers blood sugar and to track any side effects over 8-10 months. Participants completed a questionnai…

This study tested whether a daily semaglutide tablet helps Chinese adults with overweight or obesity lose weight. About 200 participants took either the drug or a placebo for 44 weeks, along with guidance on diet and exercise. The main goals were to measure the percentage of weig…

This study tested a new insulin that is injected just once a week against a standard daily insulin in 582 adults with type 2 diabetes. The goal was to see if the weekly insulin controls blood sugar as well as the daily one. Participants also used mealtime insulin. The trial laste…

This study tested a new insulin, icodec, that is injected just once a week, against a standard daily insulin (glargine) in 984 adults with type 2 diabetes who had never used insulin before. The goal was to see if the weekly insulin controls blood sugar as well as the daily one. P…

This study tested an experimental drug, ziltivekimab, in 36 adults with advanced chronic kidney disease (not on dialysis) to see if it can safely reduce inflammation and related heart risks. Participants received either a low dose, a high dose, or a placebo injection every 4 week…

This study tested whether certain drugs (NNC0194-0499, semaglutide, and cagrilintide) can reduce liver damage and alcohol use in people with alcohol-related liver disease. About 270 adults with a history of heavy drinking took part. Participants received different drug combinatio…

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (degludec), in 582 adults with type 1 diabetes. Both groups also used mealtime insulin. The goal was to see if the weekly insulin controls blood sugar as well as …

This early-stage study tested a new medicine, NNC0519-0130, given as a weekly injection to help people with obesity or type 2 diabetes. The main goals were to check for side effects and measure how the drug moves through the body. 82 participants were randomly assigned to get eit…

This study tested a new oral medicine called NDec in 96 adults with sickle cell disease. The goal was to see if it safely raises hemoglobin levels and reduces painful crises. Participants took capsules twice weekly for about a year, with some also continuing their usual hydroxyur…

This study tested a new experimental medicine called CagriSema (a combination of cagrilintide and semaglutide) against the approved drug tirzepatide for weight loss in 809 adults with obesity. Participants received weekly injections under the skin, with doses gradually increased.…

This study tested a new investigational medicine called CagriSema in 189 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either CagriSema or a placebo injection once a week for about a year. The main goal was…

This study looked at whether semaglutide, a type 2 diabetes medicine, can reduce the risk of major heart problems like heart attacks, strokes, or heart-related death. About 9,600 adults with type 2 diabetes and existing heart disease took either semaglutide tablets or a placebo d…

This study tested a new once-weekly growth hormone injection (NNC0195-0092) against the standard daily growth hormone shot in 76 children with growth hormone deficiency who had never been treated before. The goal was to see if the weekly shot worked as well for helping kids grow …

This study tested a new medicine called CagriSema (a mix of two drugs) in 331 East Asian adults with obesity or overweight. Participants received a weekly injection for about 1.5 years. The main goal was to see how much weight they lost compared to another drug. The study is comp…

This study looked at how safe it is for people with hemophilia A to switch from their current medicine (emicizumab) to a new one called Mim8. Mim8 helps prevent bleeding episodes by doing the job of the missing clotting factor. The study included 61 adults and teens who received …

This study looked at how well oral semaglutide works for Thai adults with type 2 diabetes. Researchers reviewed medical records of 209 patients to see changes in blood sugar and body weight over 6 to 12 months. The goal was to understand if this daily pill helps manage diabetes e…

This study tested a new fast-acting insulin (faster aspart) against a standard insulin (NovoRapid) in 331 adults with type 1 or type 2 diabetes. Participants took either insulin four times daily along with a long-acting insulin, with or without metformin. The main goal was to see…

This study tested a once-weekly injection of semaglutide (2.4 mg) to help people with overweight or obesity lose weight. About 375 adults took part, some receiving the drug and others a placebo, along with lifestyle advice. The main goal was to see how much weight they lost over …

This study tested whether oral semaglutide, a drug already used for diabetes, can slow the progression of early Alzheimer's disease. About 1,840 people with mild cognitive impairment or mild dementia took either the drug or a placebo for up to 3 years and 4 months. Researchers me…

This study looked at whether a once-weekly medicine called semaglutide (used for weight loss and diabetes) can lower the risk of heart attacks, strokes, and death in people with overweight or obesity. Researchers analyzed medical records of over 285,000 people in the US. The goal…

This study tested how well semaglutide (Wegovy) helps people with obesity lose weight compared to four other approved weight loss medications. About 500 employees from three US companies took part. The goal was to see which drug works best for weight loss and improves quality of …

This early-stage study tested a new medicine, NNC0519-0130, in 20 overweight or obese Chinese men. The goal was to see how the drug moves through the body and if it is safe. Participants received either the drug or a placebo for about 28 weeks. This is not a cure, but aims to hel…

This study tested a new drug called NNC0487-0111, given as an injection under the skin, to see if it is safe and how it works in the body. It included 125 adults aged 18-55 who were overweight or obese. The goal was to help manage weight, but ongoing treatment may be needed.

This study tested whether higher daily doses (25 mg and 50 mg) of the oral diabetes medication semaglutide (Rybelsus®) work better than the standard 14 mg dose in adults with type 2 diabetes. About 1,600 participants took one tablet daily for 68 weeks, with doses gradually increa…

This study looked at how well the once-daily pill Rybelsus® works for adults with type 2 diabetes in Saudi Arabia. Researchers tracked changes in blood sugar and body weight over 8-10 months. Participants took the medication as prescribed by their doctor and filled out a question…

This study tested whether a new medicine called CagriSema (a combination of two drugs) can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and overweight or obesity. About 626 participants received either CagriSema, one of the two drugs alone, or a pl…

This study looked at whether using a smart insulin pen (NovoPen 6) with two insulins (Tresiba and Fiasp) helps people with type 1 diabetes achieve better blood sugar levels. About 411 adults took part for 9-11 months, using their own continuous glucose monitor and a mobile app to…

This study tested a new medicine called Mim8 in 281 adults and teens with hemophilia A, including those whose bodies make antibodies that block standard treatment. Mim8 helps replace the missing clotting factor and is given as a weekly or monthly injection under the skin. The goa…

This study tested a drug called Ziltivekimab in 264 people with advanced chronic kidney disease and high inflammation. The goal was to see if the drug could lower inflammation markers and find the best dose for a future heart study. Participants received monthly injections of eit…

This study tested a new insulin called icodec that is injected just once a week, compared to a standard daily insulin (degludec), in 526 adults with type 2 diabetes. The goal was to see if the weekly insulin controls blood sugar as well as the daily one over 26 weeks. Participant…

This study tested three different doses of semaglutide (2 mg, 8 mg, and 16 mg) in 245 adults with type 2 diabetes and overweight who were already taking metformin. The main goals were to see how well each dose lowered blood sugar and body weight over 40 weeks. Participants receiv…

This study tested a new medicine called dasiglucagon against the standard glucagon for treating severe low blood sugar in Asian adults and Japanese teens with type 1 diabetes. About 38 participants received both drugs in random order to see if dasiglucagon raises blood sugar just…

This study compares a once-daily pill called RYBELSUS® (oral semaglutide) to other diabetes pills in adults with type 2 diabetes who are already taking metformin. About 1,020 participants will be randomly assigned to receive either RYBELSUS® or another oral glucose-lowering medic…

This study looked at how safe a new once-weekly insulin (insulin icodec) is during exercise and long periods without food in 30 adults with type 2 diabetes. Participants first took a daily insulin for a week, then switched to the weekly insulin for up to 14 weeks. The goal was to…

This study followed 99 adults with type 2 diabetes who were already prescribed oral semaglutide (Rybelsus) by their doctor. Researchers collected data from routine clinic visits and questionnaires over 8-10 months to see how well the medication controlled blood sugar and affected…

This early study tested a new medicine, NNC0519-0130, in 161 people to see if it is safe and how it works in the body. The medicine aims to lower blood sugar and reduce appetite, which could help people with type 2 diabetes and overweight. Participants received either the medicin…

This study tested a new once-weekly injection called IcoSema (a mix of two diabetes drugs) against daily insulin in 679 adults with type 2 diabetes whose blood sugar was not well controlled with daily basal insulin. The goal was to see if the weekly shot works as well or better a…

This study looked at the safety and effectiveness of Xultophy, a combination insulin and GLP-1 medicine, in 750 adults with type 2 diabetes in Korea. Participants used the drug as their doctor prescribed during routine care for about 26 weeks. The goal was to track side effects a…

This study looked at how well the diabetes pill Rybelsus (oral semaglutide) works in real life for adults with type 2 diabetes in Sweden. Researchers tracked blood sugar levels and weight changes over 8-10 months in 194 people who were already prescribed the medication by their d…

This study tested whether adding a new medicine (NNC0165-1875) to the existing weight loss drug semaglutide helps people with obesity lose more weight. 120 adults with a BMI between 30 and 45 took part. Participants received either the new drug plus semaglutide or a placebo plus …

This study tested a new medicine called Mim8 for people with hemophilia A, a condition where blood doesn't clot properly. Mim8 is given as a shot under the skin to help prevent bleeding episodes. The trial included 275 healthy volunteers and people with hemophilia A, with or with…

This study followed 244 adults with type 2 diabetes in Japan who were already prescribed Xultophy by their doctor. Researchers tracked blood sugar levels and low blood sugar episodes over 26 weeks to see how well the treatment works in everyday life. The goal was to understand re…

This study tested whether a weekly injection of semaglutide (2.4 mg) helps Asian adults with obesity (BMI 25 or higher) lose weight. About 150 participants received either the drug or a placebo for 44 weeks, along with diet and exercise advice. The main goal was to see how much w…

This study tested a new medicine called nonacog beta pegol (N9-GP) in 54 children under 6 years old with severe hemophilia B (a bleeding disorder). The goal was to see if the drug is safe and effective at preventing and treating bleeding episodes. The children received regular in…

This study looked at how quickly a fast-acting insulin (faster aspart) enters the blood in 23 Chinese adults with type 1 or type 2 diabetes. Participants received one injection of faster aspart and one of the standard insulin NovoRapid, in random order. Blood samples were taken o…

This study looked at how well the diabetes pill Rybelsus (oral semaglutide) works in everyday life for adults with type 2 diabetes in Canada. About 194 people took the medication as prescribed by their doctor and filled out questionnaires over 8-10 months. The main goal was to se…

This study looked at whether semaglutide, a medicine used for diabetes and weight loss, can reduce inflammation in the brain and body of people with early Alzheimer's disease. Twenty-three participants with mild memory problems or mild dementia received either semaglutide or a pl…

This study tested a new medicine called NNC-0156-0000-0009 (also known as nonacog beta pegol) in 25 children with hemophilia B, a bleeding disorder. The goal was to see if the drug is safe, helps prevent bleeding episodes, and how the body processes it. Children received the drug…

This study followed 291 adults with type 2 diabetes whose blood sugar was not well controlled on their current medication (DPP4i). Participants switched to an oral version of semaglutide, a drug that helps lower blood sugar and may aid weight loss. Over about 5-6 months, research…

This completed Phase 3 trial tested whether a weekly injection of semaglutide (2.4 mg) could help people with obesity and knee osteoarthritis lose weight and reduce knee pain. 407 participants received either semaglutide or a placebo, along with diet and exercise advice, over 68 …

This completed phase 1 trial tested whether CagriSema, a combination of two drugs (cagrilintide and semaglutide), can reduce how much people with overweight or obesity eat, curb their appetite, and slow stomach emptying. 62 participants received either CagriSema or a placebo for …

This study looked at whether a weekly injection of semaglutide (a medicine also used for weight loss) can improve heart failure symptoms and daily function in people with obesity-related heart failure. 529 adults with a BMI of 30 or higher took part. Participants received either …

This study tested a combination medicine called CagriSema (cagrilintide and semaglutide) in 164 adults with overweight or obesity. Researchers measured changes in appetite, food intake, and brain activity using scans. The goal was to understand how the medicine affects hunger sig…

This study looked at a new fast-acting insulin (NNC0471-0119) given through an insulin pump in 65 adults with type 2 diabetes. Researchers measured how quickly the insulin entered the bloodstream and lowered blood sugar, comparing it to a standard insulin called aspart. The goal …

This study looked at how people with type 1 or type 2 diabetes felt about using the DuraTouch® device. Over 12 weeks, 128 participants rated how easy, convenient, and satisfying the device was to use. The goal was to see if the device makes daily diabetes care simpler and more co…

This study looked at whether a weekly injection of semaglutide can improve daily life and reduce symptoms in people with obesity-related heart failure and type 2 diabetes. About 617 adults took part, receiving either the drug or a dummy shot for about a year. Researchers measured…

This study tested whether semaglutide, a diabetes medicine, improves walking ability in people with type 2 diabetes and peripheral artery disease (narrowed leg arteries). About 792 adults received weekly injections of semaglutide or a placebo for 59 weeks. The main goal was to se…

This study looked at how a high-fat meal changes the amount of the drug etavopivat in the blood of 16 healthy adults. Participants took a single dose of etavopivat after eating a high-fat meal and on an empty stomach on separate days. The goal is to understand if food affects how…

This completed Phase 1 trial looked at whether a new experimental drug called NNC0519-0130 changes how the body processes a common birth control pill. It also checked if the drug affects how fast the stomach empties. The study involved 47 healthy postmenopausal women and lasted a…

This study checks whether etavopivat, a new medicine for sickle cell disease and thalassemia, changes the heart's electrical activity. It involves 33 healthy adults who receive different doses of the drug, a placebo, or an approved heart medication. The goal is to ensure the drug…

This study looks at how the drug etavopivat is handled by the body in people with mild, moderate, or severe liver disease compared to those with healthy livers. 48 adults received a single dose, and researchers measured drug levels in the blood over 7-9 days. The goal is to under…

This completed study from Novo Nordisk looked at 756 adults in the Middle East who have heart disease with or without kidney disease. Researchers measured levels of a protein called hsCRP, which indicates inflammation throughout the body. Participants had one clinic visit and con…

This study tested a single injection of a new drug, NNC0194-0499, in 33 adults with either normal liver function or mild to severe liver impairment. The drug is being developed for non-alcoholic fatty liver disease (NAFLD) and its more serious form, NASH. The main goal was to see…

This completed Phase 1 study in 34 adults with overweight or obesity examined whether CagriSema (a combination of cagrilintide and semaglutide) changes how the body processes atorvastatin (a cholesterol drug) and warfarin (a blood thinner). Participants took single doses of atorv…

This early-stage trial tested a single injection of the experimental drug NNC0582-0001 in 56 healthy adults to see if it is safe and how the body processes it. Participants received either the drug or a placebo and were followed for a year. The study is complete, but it was not d…

This completed Phase 1 trial tested a new formulation of oral semaglutide in 264 healthy participants. The goal was to compare how much of the drug gets into the blood from the new tablet versus the current version. Participants took different doses over 21 weeks, and researchers…

This completed study looked at how well doctors can detect serious and non-serious side effects of the weight-loss drug Saxenda (liraglutide) in 27 Mexican patients with obesity. The main goal was to track cases of pancreatitis and other possible drug reactions. Patients took Sax…

This study looked at how a new insulin (NNC0363-1063) interacts with a non-glucose carbohydrate (a type of sweetener) in 36 adults with type 1 diabetes. Participants received fixed doses of the insulin and different amounts of the carbohydrate in random order over 4 tests. The go…

This study looked at how common weight-related health problems are in people of different weights in India, Pakistan, Philippines, and Vietnam. Researchers tracked 1,170 adults for about 2 years without giving any treatment. The goal was to understand which weight groups have mor…

This study looked at two weight-loss medicines, cagrilintide and semaglutide, given to 40 adults with overweight or obesity. For 14 weeks, everyone got separate shots. Then, for 8 weeks, some got a combined single shot while others kept separate shots. The goal was to measure med…

This study examined how often adults with obesity in the Gulf region have related health issues like diabetes, high blood pressure, and heart disease. Researchers also looked at the medical costs and healthcare use tied to these conditions. The goal was to better understand the r…

This early-stage study tested a new medicine called NNC0581-0001 in 48 adults, including healthy volunteers and people with fatty liver (hepatic steatosis). The main goal was to check safety and how the drug moves through the body after a single injection under the skin. Particip…

This study tested a single dose of the experimental drug etavopivat in 24 healthy Chinese adults. Researchers measured how the drug moves through the body and checked for side effects over about a week. The goal was to gather safety and dosing information for future studies in pe…

This completed Phase 1 study in 37 healthy adults tested whether a new drug called etavopivat affects how the body processes five common medicines: digoxin, rosuvastatin, midazolam, pitavastatin, and metformin. Participants took etavopivat daily for 10 days along with single dose…

This study surveyed 608 heart and kidney doctors to understand their awareness and use of a blood test called hsCRP, which measures inflammation. The goal was to learn what doctors think about inflammation's role in treating patients with heart disease, kidney disease, or heart f…

This study looked at health data from over 550,000 Chinese adults to see how being overweight or obese affects heart disease. Researchers used national survey information to find out how common heart problems are in this group and how they change over time. No treatments were giv…

This study looked at how a new medicine for type 2 diabetes, called NNC0519-0130, is processed in the body when people have different levels of kidney function. 36 adults with normal, mildly, moderately, or severely reduced kidney function received a single dose. Researchers meas…

This study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal…

This study follows people who were in the SELECT trial to see how their health changes over the next 10 years. No new medicine is given—participants just fill out a health questionnaire every 6 months. The goal is to learn about long-term effects like heart attacks, cancer, weigh…

This study tested a new insulin called insulin icodec in 18 children and teenagers (ages 10 to 17) with type 2 diabetes. Each participant received a single injection based on their body weight, and researchers measured how the insulin moved through their blood over time. The goal…

This study watched 23 people with hemophilia A who were already using Esperoct as part of their normal care. Researchers tracked side effects and how well the medicine worked over about two years. The goal was to confirm the drug's safety and effectiveness in everyday use, not to…

This early-stage study tested a single dose of the experimental medicine NNC0662-0419 in 100 adults with overweight or obesity. Participants were Japanese, Chinese, or non-Asian to see how the drug behaves in different ethnic groups. The main goals were to measure drug levels in …

This study analyzed health records from nearly 195,000 people in Denmark, Sweden, and Norway to see if semaglutide (the drug in Ozempic and Rybelsus) is linked to a higher risk of pancreatic cancer. Researchers compared new users of semaglutide to new users of other diabetes medi…

This study looked at how semaglutide, a diabetes medicine, affects the kidneys in people with type 2 diabetes and chronic kidney disease. 106 participants received either semaglutide or a placebo injection once a week for about a year. Researchers used MRI scans, blood and urine …

This early-stage study tested a new oral medicine, NNC0705-0001, in 116 healthy adults to see if it is safe and how the body handles it. The drug is being developed to treat chronic inflammation, which can lead to heart and metabolic diseases. Participants received either the dru…

This study looked at how the liver affects the body's processing of cagrilintide, a drug being developed for weight management. It involved 32 participants with different levels of liver function and healthy volunteers. The goal was to measure drug levels in the blood, not to tre…

This study tested two different versions (a tablet and a capsule) of an experimental medicine called NDec, which is being developed for sickle cell disease. 44 healthy adults each took a single dose of both forms to see how the body absorbs them. The goal was to compare the two f…

This study gathered information from 1,061 adults in Saudi Arabia about their weight, blood sugar, heart health, and lifestyle. The goal was to understand how common heart disease is in people with obesity. Participants filled out a questionnaire during a routine doctor visit, an…

This early-stage study tested a new medicine, NNC0650-0013, which may one day treat type 2 diabetes. Eleven healthy men received a single injection of the drug or a placebo to check for safety and how the body processes it. The study lasted 11 to 17 weeks and required some overni…

This early-stage study tested a new experimental drug, NNC0113-6856, in 70 healthy men to see if it is safe and how the body processes it. Participants received either a single oral dose or an injection into the vein. The goal was to gather initial safety data and measure drug le…

This study tested whether a new pen injector delivers the drug Mim8 into the blood as well as a standard syringe and cartridge. 205 healthy men received a single injection of Mim8 using either the pen or the syringe. The goal was to see if the pen works just as well, making it ea…

This study surveyed 1,500 Chinese heart and kidney specialists to understand their awareness and perceptions of systemic inflammation in patients with both atherosclerotic cardiovascular disease and chronic kidney disease. The goal was to learn how doctors currently identify and …

This study looked at how different amounts of water and delays before breakfast affect levels of a new semaglutide tablet in the blood. It involved 121 healthy men who took the tablet daily for 10 days. The goal was to find the best way to take the medicine for future use.

This completed Phase 1 study tested two different versions of the experimental drug NNC0519-0130 in 46 adults with overweight or obesity. The main goal was to measure how much of the drug gets into the blood and compare the two formulations. Participants received both versions by…

This study tested a single dose of the experimental drug monlunabant in 73 healthy men of normal weight, half of Japanese descent and half of Caucasian descent. The main goal was to check for side effects and see how the drug moves through the body. Participants were randomly ass…

This study tested how different versions of the experimental drug ziltivekimab move through the body when given as a single injection under the skin. It compared two different formulas and two injection methods: a manual syringe and a pen-injector. The study involved 267 healthy …

This study tested four different tablet versions of the medicine semaglutide in 90 healthy men. The goal was to see how each tablet is absorbed into the body, not to treat any disease. Participants were randomly assigned to receive one of the tablet versions, and the study lasted…

This study tested whether health data can be collected remotely from adults with overweight or obesity using a smartphone app and connected devices like a watch and scale. 146 participants took part for 24 weeks without any study medicine. The goal was to learn how to run future …